we are a biopharmaceutical company specializing in the development of novel therapeutics to treat diseases of the back of the eye, with a focus on developing therapeutics for age-related macular degeneration (amd).
Company profile
Ticker
ISEE
Exchange
Website
CEO
Glenn Sblendorio
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Ophthotech Corp.
SEC CIK
Corporate docs
Subsidiaries
IVERIC bio Gene Therapy LLC • Orion Ophthalmology LLC • IVERIC bio Europe Limited ...
ISEE stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
21 Jul 23
EFFECT
Notice of effectiveness
18 Jul 23
25-NSE
Exchange delisting
11 Jul 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Jul 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Jul 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Jul 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Jul 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Jul 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Jul 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Jul 23
Transcripts
ISEE
Earnings call transcript
2022 Q3
3 Nov 22
ISEE
Earnings call transcript
2022 Q2
26 Jul 22
ISEE
Earnings call transcript
2022 Q1
4 May 22
ISEE
Earnings call transcript
2021 Q4
24 Feb 22
ISEE
Earnings call transcript
2021 Q3
9 Nov 21
ISEE
Earnings call transcript
2021 Q2
4 Aug 21
ISEE
Earnings call transcript
2021 Q1
5 May 21
ISEE
Earnings call transcript
2020 Q4
3 Mar 21
ISEE
Earnings call transcript
2020 Q3
2 Nov 20
ISEE
Earnings call transcript
2020 Q3
2 Nov 20
Latest ownership filings
SC 13G/A
Deep Track Capital, LP
14 Feb 24
4
Mark S. Blumenkranz
13 Jul 23
4
David Francis Carroll
13 Jul 23
4
Christine Ann Miller
13 Jul 23
4
Adrienne L Graves
13 Jul 23
4
Calvin W. Roberts
13 Jul 23
4
GLENN SBLENDORIO
13 Jul 23
4
Christopher Paul Simms
13 Jul 23
4
Pravin Dugel
13 Jul 23
4
Jane Henderson
13 Jul 23
Financial summary
Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 467.57 mm | 467.57 mm | 467.57 mm | 467.57 mm | 467.57 mm | 467.57 mm |
Cash burn (monthly) | 2.91 mm | (no burn) | 24.61 mm | 19.09 mm | 16.86 mm | 14.74 mm |
Cash used (since last report) | 37.31 mm | n/a | 315.49 mm | 244.68 mm | 216.16 mm | 188.90 mm |
Cash remaining | 430.26 mm | n/a | 152.08 mm | 222.89 mm | 251.41 mm | 278.67 mm |
Runway (months of cash) | 147.8 | n/a | 6.2 | 11.7 | 14.9 | 18.9 |
Institutional ownership, Q2 2023
99.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 264 |
Opened positions | 111 |
Closed positions | 69 |
Increased positions | 56 |
Reduced positions | 69 |
13F shares | Current |
---|---|
Total value | 5.14 tn |
Total shares | 137.19 mm |
Total puts | 4.41 mm |
Total calls | 11.35 mm |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 13.68 mm | $538.12 bn |
BLK Blackrock | 10.79 mm | $424.46 bn |
Avoro Capital Advisors | 8.05 mm | $316.69 bn |
Ubs Oconnor | 5.85 mm | $230.14 bn |
Beryl Capital Management | 5.34 mm | $210.06 bn |
STT State Street | 4.68 mm | $184.03 bn |
GS Goldman Sachs | 4.22 mm | $166.10 bn |
Millennium Management | 3.96 mm | $155.78 bn |
Flynn James E | 3.42 mm | $0.00 |
DB Deutsche Bank AG - Registered Shares | 3.19 mm | $125.59 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Jul 23 | Bolte Axel | Common Stock | Sale back to company | Dispose D | No | No | 0 | 22,088 | 0.00 | 0 |
11 Jul 23 | Bolte Axel | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 9.94 | 23,186 | 230.47 k | 0 |
11 Jul 23 | Bolte Axel | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 6.82 | 15,500 | 105.71 k | 0 |
11 Jul 23 | Bolte Axel | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 4.14 | 16,000 | 66.24 k | 0 |
11 Jul 23 | Bolte Axel | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 1.39 | 16,000 | 22.24 k | 0 |
11 Jul 23 | Bolte Axel | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 2.775 | 16,000 | 44.40 k | 0 |
11 Jul 23 | Bolte Axel | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 2.46 | 16,000 | 39.36 k | 0 |
11 Jul 23 | Bolte Axel | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 7,500 | 0.00 | 0 |
11 Jul 23 | Anthony S Gibney | Common Stock | Sale back to company | Dispose D | No | No | 0 | 40,291 | 0.00 | 0 |
11 Jul 23 | Anthony S Gibney | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 22.57 | 50,000 | 1.13 mm | 0 |